Internal Medicine, Hematology & Oncology · Santa Monica, CA
NPI
1750593844
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2020 Santa Monica Blvd, Suite 600
Santa Monica, CA, 90404
Phone (310) 633-8400
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
67,586 services
Medicare patients, 2024
444
Average age 74
Drug cost, 2024
$4.7M
549 prescriptions
Company payments, 2025
$40K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan W Goldman was code J1453 (injection, fosaprepitant, 1 mg), 10,800 times for 24 patients. In total Jonathan W Goldman billed 67,586 services in 142 codes, and Medicare paid $1.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-11-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 10,800 | 24 | $0.15 | $1,592 |
| J9304 Injection, pemetrexed (pemfexy), 10 mg | Office | 7,055 | 16 | $43.95 | $310K |
| J0897 Injection, denosumab, 1 mg | Office | 4,860 | 23 | $20.63 | $100K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,310 | 37 | $0.73 | $950 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,308 | 38 | $0.13 | $168 |
| 99215 Office E&M - Established | Office | 1,096 | 288 | $150.71 | $165K |
| 85025 Blood Count | Office | 791 | 254 | $7.61 | $6,020 |
| 80053 Clinical Chemistry | Office | 746 | 243 | $10.35 | $7,718 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 633 | 258 | $13.72 | $8,688 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 407 | 51 | $0.52 | $210 |
| J9045 Injection, carboplatin, 50 mg | Office | 383 | 17 | $2.85 | $1,090 |
| 96375 Injection Administration | Office | 362 | 51 | $13.73 | $4,971 |
| 82378 Clinical Chemistry | Office | 337 | 135 | $18.58 | $6,261 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 240 | 11 | $0.07 | $17.32 |
| 96413 Chemotherapy Administration | Office | 218 | 64 | $99.03 | $22K |
By year: 2022 $1.2M for 52,712 services; 2023 $1.3M for 60,598 services; 2024 $1.6M for 67,586 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 791 | 254 | $7.61 | $6,020 |
| 80053 Clinical Chemistry | 746 | 243 | $10.35 | $7,718 |
| 82378 Clinical Chemistry | 337 | 135 | $18.58 | $6,261 |
| 83615 Clinical Chemistry | 42 | 35 | $5.92 | $249 |
| 83735 Clinical Chemistry | 27 | 18 | $6.57 | $177 |
| 36415 Venipuncture Blood Collection | 26 | 15 | $8.65 | $225 |
| 84100 Clinical Chemistry | 25 | 15 | $4.65 | $116 |
| 84443 Clinical Chemistry | 23 | 17 | $16.46 | $379 |
| 86301 Immunoassay | 19 | 14 | $20.39 | $387 |
| 82607 Clinical Chemistry | 12 | 12 | $14.78 | $177 |
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan W Goldman prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 177 prescriptions and refills. In total Jonathan W Goldman wrote 549 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 177 | 177 | 21 | $3.0M |
| Escitalopram Oxalate Generic | 26 | 34 | Under 11 | $158 |
| Prochlorperazine Maleate Generic | 25 | 25 | 18 | $437 |
| Lorbrena Lorlatinib | 22 | 22 | Under 11 | $417K |
| Dexamethasone Generic | 20 | 21 | 14 | $553 |
| Ondansetron Hcl Generic | 19 | 19 | 16 | $206 |
| Alecensa Alectinib Hcl | 13 | 13 | Under 11 | $241K |
| Erivedge Vismodegib | 13 | 13 | Under 11 | $175K |
| Bupropion Hcl Sr Bupropion Hcl | 11 | 11 | Under 11 | $106 |
| Mektovi Binimetinib | 11 | 11 | Under 11 | $166K |
| Braftovi Encorafenib | 11 | 11 | Under 11 | $177K |
Brand drugs: 304 claims; generic drugs: 245 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan W Goldman $40K ($37K in general payments such as food, travel and fees and $3,269 for research) from 15 companies. The largest payer was Abbvie Inc. with $19K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 9 | $19K |
| Daiichi Sankyo Inc. 4568.T | 1 | $7,203 |
| Eli Lilly and Company LLY | 5 | $5,388 |
| Pfizer Inc. PFE | 3 | $3,090 |
| Genentech USA, Inc. ROG.SW | 3 | $2,994 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $2,292 |
| GlaxoSmithKline, LLC. GSK | 1 | $64.5 |
| Array Biopharma Inc PFE | 3 | $42.4 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $30.5 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.